Skip to main content
HR 919 119th Congress House Taxation Health care costs and insurance Health care coverage and access Health promotion and preventive care Income tax deductions

Chronic Disease Flexible Coverage Act

Introduced: February 4, 2025 Introduced by: Buchanan, Vern Republican · Florida See on congress.gov
 Everywhere this bill has been 9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 5, 2025
Received in the Senate and Read twice and referred to the Committee on Finance.
Mar 4, 2025
Motion to reconsider laid on the table Agreed to without objection.
Mar 4, 2025
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)
Mar 4, 2025
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)
Mar 4, 2025
DEBATE - The House proceeded with forty minutes of debate on H.R. 919.
Mar 4, 2025
Considered under suspension of the rules. (consideration: CR H964-966)
Mar 4, 2025
Mr. Smith (MO) moved to suspend the rules and pass the bill.
Feb 4, 2025
Referred to the House Committee on Ways and Means.
Feb 4, 2025
Introduced in House
 Plain-English summary Congressional Research Service

Chronic Disease Flexible Coverage Act

This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.

Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. 

The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include

  • angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;
  • anti-resorptive therapy for individuals with osteoporosis or osteopenia;
  • beta-blockers for individuals with congestive heart failure or coronary artery disease;
  • blood pressure monitors for individuals with hypertension;
  • inhaled corticosteroids and peak flow meters for individuals with asthma;
  • insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;
  • international normalized ratio testing for individuals with liver disease or bleeding disorders;
  • low-density lipoprotein testing for individuals with heart disease;
  • statins for individuals with heart disease or diabetes; and
  • selective serotonin reuptake inhibitors for individuals with depression. 

The bill provides statutory authority for the IRS's guidance. 

What's happening now March 5, 2025

Received in the Senate and Read twice and referred to the Committee on Finance.

 Committees of jurisdiction 2